Member Info for TRENCH123

There is a disparity between 1. what the company is saying which is very positive and based on a longer term perspective and 2. what many non-investors or short-term traders are saying which is negative and based on historical performance not future prospects

Poor sentiment has been driving the price down, but a major announcement and this will change

Trout, had not seen the RNS but thanks for pointing it out. Ryan has been supportive of the company in a genuine way which is appreciated

With 25 million shares traded it certainly can be liquid, but trying to buy and sell at a profit in just a few hours is not to be recommended on any AIM company

KingH, I refer to your comments 'PYC has precision dosing tool application currently in trials with Beyond Blood Diagnostics and the NHS.....and a Heads of Terms agreement with DosemeRX.....' and the trials are due to complete in the New Year....This tool has taken years to develop and is coming to its commercialisation point'

It was Jim who 'kicked off' the personalised dosing initiative and I believe that he still a driving force behind it. I have noticed that he is always happy to answer any DoseMe-related questions in the IMC presentations and he will be extremely keen to see things to a successful outcome. The recent comment that PYC are making 'significant progress across our personalised medicine dosing software initiative' suggests to me that a commercial deal is likely

I know a number of people here paint a negative picture and on the basis of the share price movement alone it is understandable. The Directors are disappointed with the share price, just like investors. They recognise that it is a key factor in assessing their performance and it must improve and have committed to this at the IMC presentations

PYC have been through the process of change but they now have a strong team profile, steady business growth across a broader client base with better more consistent cashflow, some excellent partnerships and potentially some important commercial news on the horizon. The company is actually better placed than it has ever been IMHO. Sentiment is key, as with all AIM companies, and I believe this will change for the better and we will then see how the price responds

The contracts announced today were small, but £30k for one months work on top of the various contracts they are currently working can only be a positive, especially with the opportunity for follow-on business. I believe we will see more important announcements before year-end

They also highlight the commitment of PYC to diversifying its client base as well as expanding into therapeutic areas beyond oncology. This is clearly a good move on the part of the company and will help secure its future growth IMHO

People with a genuine interest in investing here (as opposed to short-term trading) please do watch the recent in-depth IMC presentation

Then make your own judgement

I would suggest people re-visit the recent IMC presentation. Extremely positive and progressive, not that of a sub £1m company

I am keen to hear further details about the expanded partnership with DoseMe. This could be very interesting

Being an AIM CEO is no easy task in challenging market conditions. Despite this Pete has moved the company forward (albeit the share price has not been kind to him) and their is plenty to build on, as evidenced by Jim's comments :-

'We are excited for the next stage in Physiomics' growth and at the same time wish Pete all the very best and thank him for enabling us to start the current financial year ending 30 June 2026 with a record level of contracted projects, a new biometrics service-line already generating revenue, and significant progress across our personalised medicine dosing'

Trout, still maintain same response, paper loss only. I know AIM is not risk free, but just taken a few more at 0.29. I will not moan if it doesn't work out, my decision

Company busy working on multiple contracts, lets see how it pans out

Holders are not getting burned, it is sellers who are getting burned. Their choice

I have been looking back at the progress made by PYC in the first six months of the year (see linkedIn post of 9th July) and included a few extracts :-

We kicked off the year with a series of publications that showcase our commitment to advancing drug development through Model-Informed Drug Development (MIDD). These publications, each written with esteemed partners (1) Astellas Pharma , (2) Merck KGaA, Darmstadt, Germany , and (3) Ankyra Therapeutics , explore how modelling and simulation techniques can be used to better understand your drug’s behaviour and enable model informed,

de-risked decision-making in early drug development

We released two blog posts in collaboration with Weatherden, unpicking some of the details from the FDA ’s updated guidance on dose optimisation for oncology drugs. These articles are crucial as the industry adapts to new standards in drug development, considering both Project Optimus requirements and how MIDD can guide smarter decision-making in translational and clinical development strategies

Beyond the award of two new contracts in the biometrics space, we were are also very pleased to have announced several exciting projects in the Modelling and Simulation service area, including :-

1) Multiple projects with an existing large pharma partner, utilising our Virtual Tumour platform to model targeted oncology agents in monotherapy and combinations in a range of oncology indications

2) Multiple projects with existing client Numab Therapeutics AG across their pipeline of next-generation immunology and immuno-oncology drugs

3) Three new UK-based clients, collaborating on projects to : Inform the design of a Phase 2 study for a small molecule designed to treat rheumatoid arthritis ; Predict the human PK of a first-in-class bifunctional antibody therapy designed to target multiple solid tumour indications to support progression into a First-in-Human study ; Inform optimal dosing for an upcoming First-in-Human trial of an Antibody-Drug Conjugate (ADC)

The news flow in the second half of the year has been disappointing to date. However, I would hope that the momentum generated in the first half is continuing and look forward to a news-rich period in the run up to the year-end, allowing PS to provide a similarly upbeat review for the second half around the year-end

Ralph, think the likely completion of trial is now around end of March

Last trade at 0.37 was a buy, it was mine

Laura, some good points which put things in perspective

Burt, I agree with your comments about the current SP and the need to hold tight in the event that a raise is initiated

I am intrigued by the following comments about PYC included as part of the IMC presentation from last month

'Supported by blue-chip client relationships, increasing diversification, and a robust cash position, the Group is confident in delivering sustainable growth, enhanced profitability, and long-term shareholder value'

These comments were clearly prepared specifically for the presentation as no such resume has appeared previously on IMC. Have things deteriorated to such an extent that the comments are no longer relevant ? I would certainly hope not. Hence, I remain cautiously positive like you Burt

Satan, not sure that the 'pump and dump' comment is relevant here. The price has been relatively stable in a narrow price range for 6 months plus, awaiting significant news - be it good or bad - which will result in a permanent re-rate

Lot of posters on here today who are incapable of making their own investment decisions and blame others for their shortcomings and losses. They live in their own little bubble, obsessed by money. Their childish utterings will achieve nothing, but if it keeps them happy and contented then so be it. If comments stay focused on PYC then I have no issues

Standard resolution for many on AIM, nothing unusual here

All resolutions passed, as expected

Bassman, it is a site for 'share chat' and not 'investment advice' and you are intelligent enough surely to understand this. Give it a rest